TSCM CAR-T Cell Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Fig.1 Scheme of TSCM-based CART Efficacy.¹

T memory stem cells are the earliest developmental stage of the memory T cells subgroup and have become a promising cell source for cellular therapy based on their long lifespan, robust proliferative potential, and self-renewal capacity.

Properties of Treg Cells

TSCM is a rare memory T cell subset, accounting for 2-4% of the total CD4+ and CD8+ T cells in the peripheral blood. TSCM shares some common marker expressions with naïve T cells (CD45RA+, CD45RO−, CCR7+, CD27+), and they also display distinguished expression markers, such as CD95, CXCR3, CXCR4, and IL-2 receptor beta (CD122). Functionally, TSCM presents many similarities to memory T cells than naïve cells, such as TSCM cells display antigen-experienced and generate some cytokines like TNF-α, IFN-γ, and IL-2 under T cell receptor (TCR) stimulation. More importantly, TSCM can differentiate into effector memory (EM) T cell and central memory (CM) T cell subsets, possessing a great self-renewal capacity and long-term dynamics in contrast to other memory T cell subsets. Based on these characteristics, it is promising to use TSCM as an ideal cell source for T-cell therapies.

The Clinical Significance of TSCM

CAR-TSCM cells have displayed therapeutic promise in diseases with many features:

As TSCM cells have excellent engraftment, long-persistence, and potent efficacy against cancer cells, it is clinically beneficial to ACT therapy.
TSCM displayed lower cytokine production (IFN-γ, TNF-α) than effector T cells, while significantly higher than naïve T cells.
TSCM can persist lone-term while maintaining precursor potential for several years post-infusion.

TSCM CAR-T Cells at Creative Biolabs

As TSCM cells have a durable and robust immune response against cancers and pathogens, TSCM cells as an ideal enrichment target for CART cell immunotherapy. TSCM cells are genetically engineered to express chimeric antigen receptors (CARs) to further improve T cell immunotherapy effectiveness. Compared to conventional TSCM cells, TSCM-based CAR-T cells can directly bind to highly specific antigens of target cells, reducing off-target effects. The use of TSCM cells as a basis for therapy has a favorable effect on safety, longevity, and efficacy. Creative Biolabs is dedicated to offering comprehensive TSCM-based CAR-T cells to meet global customers' needs. We follow high-quality manufacturing and QC standards to verify each cell line. Meanwhile, we also focus on customizing special CAR products based on the special needs of global customers. Please feel free to contact us or inquire about an appropriate product or special solution for you.

Reference

Arcangeli, S.; et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022,132(12):e150807.

Associated Antigen Target

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION